Trimel’s application of drug delivery technologies to existing molecules is intended to create innovative products for patients that are expected to be safe, easy to use and practical. Trimel has acquired or licensed the rights to two proprietary platforms and is pursuing the development and application of these technologies to several high value pharmaceutical compounds. These innovative drug delivery technology platforms consist of a bioadhesive Intranasal gel and the TriVair™ Deposition/Dispersion System, a unit dose dry powder inhaler and nasal dispersion system.











© 2014 by Trimel Pharmaceuticals Corporation